compound introduction
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3 -positive T cells and CLDN18.2 -expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma. In Vitro Gresonitamab redirects tumor cell lysis to kill tumor cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
